General Information |
| Summary |
This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2024-07-11 |
| End date (estimated) |
2029-06-30 |
| Clinical feature |
| Label |
ovarian cancer |
| Link |
http://purl.obolibrary.org/obo/DOID_2394 |
| Description |
A female reproductive organ cancer that is located_in the ovary.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT06342986 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT06342986 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/study/NCT06342986 |
| Sponsors |
Masonic Cancer Center, University of Minnesota
|
| Collaborators |
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
33 |
